Innovent Biologics Inc (F:6IB) — Market Cap & Net Worth
Market Cap & Net Worth: Innovent Biologics Inc (6IB)
Innovent Biologics Inc (F:6IB) has a market capitalization of $16.76 Billion (€14.34 Billion) as of August 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #1481 globally and #332 in its home market, demonstrating a -5.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innovent Biologics Inc's stock price €9.47 by its total outstanding shares 1734623465 (1.73 Billion). See Innovent Biologics Inc (6IB) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Innovent Biologics Inc Market Cap History: 2018 to 2026
Innovent Biologics Inc's market capitalization history from 2018 to 2026. Data shows growth from $4.81 Billion to $19.20 Billion (22.32% CAGR).
Innovent Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innovent Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.31x
Innovent Biologics Inc's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.06x
Innovent Biologics Inc's market cap is 21.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $4.81 Billion | $9.48 Million | -$5.77 Billion | 507.15x | N/A |
| 2019 | $5.88 Billion | $1.05 Billion | -$1.72 Billion | 5.61x | N/A |
| 2020 | $16.33 Billion | $3.84 Billion | -$998.42 Million | 4.25x | N/A |
| 2021 | $10.34 Billion | $4.27 Billion | -$3.14 Billion | 2.42x | N/A |
| 2022 | $7.79 Billion | $4.56 Billion | -$2.18 Billion | 1.71x | N/A |
| 2023 | $9.13 Billion | $6.21 Billion | -$1.03 Billion | 1.47x | N/A |
| 2024 | $8.84 Billion | $9.42 Billion | -$94.63 Million | 0.94x | N/A |
| 2025 | $17.14 Billion | $13.04 Billion | $813.57 Million | 1.31x | 21.06x |
Competitor Companies of 6IB by Market Capitalization
Companies near Innovent Biologics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Innovent Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Innovent Biologics Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Innovent Biologics Inc's market cap moved from $4.81 Billion to $ 19.20 Billion, with a yearly change of 22.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.20 Billion | +12.05% |
| 2025 | €17.14 Billion | +93.81% |
| 2024 | €8.84 Billion | -3.11% |
| 2023 | €9.13 Billion | +17.19% |
| 2022 | €7.79 Billion | -24.71% |
| 2021 | €10.34 Billion | -36.65% |
| 2020 | €16.33 Billion | +177.59% |
| 2019 | €5.88 Billion | +22.36% |
| 2018 | €4.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Innovent Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.76 Billion USD |
| MoneyControl | $16.76 Billion USD |
| MarketWatch | $16.76 Billion USD |
| marketcap.company | $16.76 Billion USD |
| Reuters | $16.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, a… Read more